Latest Content

Nexstim PLC
Consolidating both shares and strategy

Nexstim started 2021 on a positive footing with its Q121 business and clinical update highlighting incremental operational progress and a growing body of evidence in depression. The successful €6.4m (net) spring rights issue provides additional funds to support execution on the company’s 2020-24 corporate strategy, including funding further development of new accelerated iTBS treatment protocols. Resolutions at this week’s AGM authorised a 100 to 1 reverse share split to facilitate trading, posi

 View

  • 12 May 21
  • -
  • -
ANGLE plc
Parsortix commercial traction would be transformational

ANGLE is progressing its proprietary Parsortix cancer diagnostic platform through several key inflection points over the next 24 months, most notably FDA approval. In parallel, it has initiated commercialisation through the creation of two clinical laboratories (in the UK and US), which can offer services to the pharma industry and LDTs (Laboratory Developed Tests) for the clinical market. Parsortix is an elegant microfluidic device that captures circulating tumour cells (CTCs) for analysis. Suc

 View

  • 11 May 21
  • -
  • -
Allergy Therapeutics plc
G309 exploratory grass trial on course for H221 read-out 6 May 2021

Allergy Therapeutics has announced the completion of the treatment period for all patients in the G309 exploratory field study of Grass MATA MPL. This has been achieved despite the myriad COVID-19 restrictions and challenges in performing such a study in both Europe and the US. The lack of delay means the data readout remains on track for H221.

 View

  • 06 May 21
  • -
  • -
Futura Medical plc
MED3000 receives CE Mark as a Class II(b) device 30 April 2021

Futura Medical has received the approval certificate for MED3000 from the designated EU Notified Body. The CE Mark as a Class II(b) medical device means MED3000, a proprietary topical gel for erectile dysfunction (ED), the first clinically proven OTC treatment is approved across Europe.

 View

  • 30 Apr 21
  • -
  • -
Maxcyte
Catching an unbroken wave

MaxCyte’s strong FY20 performance was flagged in February’s trading statement. Revenues were up 21% to $26.2m despite known COVID impacts. EBITDA grew by 121% to $2.9m, before CARMA expenses, driven primarily by lower COVID spend due to pandemic-related restrictions. Potential pre-commercialisation milestones increased from >$800m to >$950m, with 140+ partnered programmes and 100+ covered by clinical licences. This operational momentum is expected to flow into FY21, with sustained revenue growth

 View

  • 27 Apr 21
  • -
  • -
Futura Medical plc
FY21 is set to be a year of execution

Futura Medical reported FY20 results in line with expectations, with net loss reduced from £8.9m to £2.4m. Net cash of £1.0m, coupled with £2.0m received in connection with the China and Far East MED3000 collaboration agreement and a £0.5m R&D tax credit, provides a cash runway that extends to Q122. The major events centre on MED3000’s progress along the respective regulatory paths in Europe and the US, with CE Marking expected by end-May. The FDA’s requirement is confirmed as a small study, FM7

 View

  • 14 Apr 21
  • -
  • -
 

Trinity Delta Research and Daily Commentaries

Research Tree offers Trinity Delta research, providing ongoing coverage of 17 shares. We offer 200 reports from Trinity Delta on Research Tree.

  • Research reports provided by Trinity Delta

  • Companies covered by Trinity Delta

  • Sectors covered by Trinity Delta